Atomo Diagnostics Ltd (AT1)

Snapshot

AT1's Principal Activity is the development and sale of medical devices.

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Ms Deborah Neff	Non-Executive Director	Sep 2021	Ms Deborah Neff Non-Executive Director Ms Neff has experience in building businesses and product commercialization in life sciences industry. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013. Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas. Deborah's work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines. Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively. Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean's Leadership Council at the University. Deborah also completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
Ms Constance (Connie) Bernadette Carnabuci	Non-Executive Director	Feb 2020	Ms Constance (Connie) Bernadette Carnabuci Non-Executive Director Ms Carnabuci has over 30 years of experience advising intellectual property and technology businesses in Australia and across Asia on commercial, corporate and regulatory matters. Ms Carnabuci holds an executive role as the General Counsel of the Australian Broadcasting Corporation. She is a professional Non-Executive Director and currently serves on the Board and the Remuneration Committee of OFX. Ms Carnabuci is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She serves as the Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.
Dr Curt Harold LaBelle	Non-Executive Director	Oct 2016	Dr Curt Harold LaBelle Non-Executive Director Dr LaBelle has been involved in the healthcare industry for 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF). He also serves as a director on the boards of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Dr LaBelle is also the member of Risk committee.
Mr John Perry Keith	Non-Executive Chairman,Non-Executive Director	Dec 2011	Mr John Perry Keith Non-Executive Chairman,Non-Executive Director Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is also the member of Risk committee.
Mr John Michael Kelly	Founder,Chief Executive Officer,Managing Director	Apr 2010	Mr John Michael Kelly Founder,Chief Executive Officer,Managing Director Mr Kelly was into developing and commercialising medical devices for more than 20 years to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of Mirage Swift and Activa mask systems.
Dr Paul Alexander Kasian	Non-Executive Director	N/A	Dr Paul Alexander Kasian Non-Executive Director Dr Kasian is an experienced executive director in both domestic and international companies in senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. Previously he served as a Non-Executive Director, then Chairman and CEO of Genetic Technologies Limited (appointed 12 December 2013 and resigned 23 September 2019). Dr Kasian is the Chair of the Risk Committee.
Ms Gillian Maria Nairn	Company Secretary	N/A
Fabio Baglioni	Chief Commercial Officer	N/A
William Souter	Chief Financial Officer	N/A
Mark Smith	Chief Operating Officer	N/A

Show All

Director Transactions

Date	Director	Type	Amount	Price	Value	Notes
09/04/21	Curt LaBelle	Buy	+960,000	$0.156	$150,000	Exercise of options
09/04/21	Curt LaBelle	Exercise	960,000	$0.156	$150,000	Exercise of options
09/04/21	Curt LaBelle	Buy	+240,000	$0.156	$37,500	Exercise of options
09/04/21	Curt LaBelle	Exercise	240,000	$0.156	$37,500	Exercise of options

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Deborah Neff	15/09/2021	0	N/A	N/A	N/A
Curt LaBelle	09/04/2021	240,000	64,811,280	2,400,000	N/A
John Kelly	30/06/2020	7,370,248	66,160,000	2,000,000	N/A
John Keith	30/06/2020	3,261,056	N/A	3,600,000	N/A
Constance (Connie) Carnabuci	30/06/2020	N/A	75,000	N/A	N/A
Paul Kasian	30/06/2020	N/A	100,000	N/A	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Dalraida Holdings Pty Limited	66,160,000	11.79%
Global Health Investment Fund I Llc	63,851,280	11.38%
Walker Group Holdings Pty Ltd	46,660,718	8.32%
National Nominees Limited	32,478,361	5.79%
J P Morgan Nominees Australia Pty Limited	18,556,834	3.31%
HSBC Custody Nominees (Australia) Limited	17,624,130	3.14%
Blueflag Holdings Pty Ltd	13,760,000	2.45%
Grand Challenges Canada	11,390,824	2.03%
Liverbird Pty Ltd	9,731,653	1.73%
Sokolov Pty Ltd	9,202,181	1.64%
I D E Pty Ltd <Atf Ide Trust>	9,032,248	1.61%
Mark Andrew Smith	7,790,224	1.39%
John Michael Kelly	7,370,248	1.31%
Leo James Lynch & Judith Anne Beswick	7,321,121	1.30%
Bnp Paribas Noms Pty Ltd	6,972,741	1.24%
Hsbc Custody Nominees (Australia) Limited A/C 2	6,528,750	1.16%
Mr Ian Fredrick Johnson	6,079,560	1.08%
Bosana Nominees Pty Ltd	5,881,496	1.05%
Ruth Karen Devney	5,626,408	1.00%
Nicola Jayne Rigby	4,846,220	0.86%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
2020	$0.34	30 June

AT1 Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.